Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

References

• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162. doi: 10.1182/blood-2008-11-185132
   PubMed Web of Science ®Google Scholar
• Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739–3749. doi: 10.1182/blood-2014-01-547695
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–1123. doi: 10.1182/blood-2005-07-2708
   PubMed Web of Science ®Google Scholar
• Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–3214. doi: 10.1182/blood-2009-10-248146
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–1876. doi: 10.1182/blood-2011-09-377713
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish adult leukemia group ALL 4-2002 MRD study. Br J Haematol. 2008;142(2):227–237. doi: 10.1111/j.1365-2141.2008.07185.x
   PubMed Web of Science ®Google Scholar
• Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910–915. doi: 10.1182/blood-2006-07-037093
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731–1738. doi: 10.1016/S0140-6736(98)04058-6
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, van der Velden VH, Bruggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009. doi: 10.1182/blood-2015-03-580027
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from children’s Oncology group study AALL0232. Blood. 2015;126(8):964–971. doi: 10.1182/blood-2015-03-633685
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120(23):4470–4481. doi: 10.1182/blood-2012-06-379040
   PubMed Web of Science ®Google Scholar
• Sutton R, Shaw PJ, Venn NC, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015;168(3):395–404. doi: 10.1111/bjh.13142
   PubMed Web of Science ®Google Scholar
• Van der Velden VH, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23(6):1073–1079. doi: 10.1038/leu.2009.17
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24(3):521–535. doi: 10.1038/leu.2009.268
   PubMed Web of Science ®Google Scholar
• Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol. 2009;146(3):292–299. doi: 10.1111/j.1365-2141.2009.07744.x
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Monitoring and managing minimal residual disease in acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2013;2013:290–293. doi: 10.1200/EdBook_AM.2013.33.290
   Google Scholar
• Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69–v82.
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Fathi A, et al. NCCN guidelines insights: acute lymphoblastic leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017;15(9):1091–1102. doi: 10.6004/jnccn.2017.0147
   PubMed Web of Science ®Google Scholar
• Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–2496. doi: 10.1182/blood-2014-09-599894
   PubMed Web of Science ®Google Scholar
• Kotrova M, van der Velden VHJ, van Dongen JJM, et al. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transplant. 2017;52(7):962–968. doi: 10.1038/bmt.2017.16
   PubMed Web of Science ®Google Scholar
• Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69(345):81–86. doi: 10.1080/01621459.1974.10480131
   Web of Science ®Google Scholar
• Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35–44. doi: 10.1002/sim.4780030106
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e225. doi: 10.1038/bcj.2014.48
   PubMed Web of Science ®Google Scholar
• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi: 10.1038/bcj.2017.53
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524–1533. doi: 10.3324/haematol.2016.144311
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786–792. doi: 10.1038/bmt.2016.20
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Socie G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the acute leukemia Working Party of the European Society for blood and marrow transplantation. Haematologica. 2017;102(1):139–149. doi: 10.3324/haematol.2016.145631
   PubMed Web of Science ®Google Scholar
• Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468–472. doi: 10.1182/blood-2012-02-409813
   PubMed Web of Science ®Google Scholar
• Huang YJ, Coustan-Smith E, Kao HW, et al. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: fusion transcripts and leukemia-associated immunophenotypes. J Formos Med Assoc=Taiwan yi zhi. 2017;116(10):774–781. doi: 10.1016/j.jfma.2016.12.002
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531. doi: 10.1182/blood-2017-08-798322
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–1180. doi: 10.1182/bloodadvances.2016001925
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar
• Pavlu J, Labopin M, Zoellner AK, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the acute leukemia Working Party of the EBMT. Cancer. 2017;123(11):1965–1970. doi: 10.1002/cncr.30604
   PubMed Web of Science ®Google Scholar